WASHINGTON--(BUSINESS WIRE)--The Biotechnology Industry Organization (BIO) today commended the United States Court of Appeals for the Federal Circuit for yesterday’s action upholding a lower court’s ruling that the District of Columbia law seeking to control the price of pharmaceutical products was unconstitutional.